News

Fierce Pharma3d
Lilly's Mounjaro shows its cardio benefits in Trulicity head-to-head trial
A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...
Lilly stock falls as Mounjaro fails to show superiority over Trulicity
Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...
Eli Lilly Weight-Loss Drug Makes Cardio Advance. More Bad News for Novo Nordisk.
Eli Lilly drug Mounjaro resulted in a lower risk of heart attacks and strokes in patients with diabetes compared with the ...
Hormone expert explains why people's sex drives go 'through the roof' when they take Mounjaro
A hormone expert has explained why some people’s sex drive goes ‘through the roof’ while using Mounjaro. Use of the drug for ...
Eli Lilly (LLY) Reveals Promising Diabetes and Alzheimer's Trials Results
Eli Lilly (LLY) has recently shared positive developments in its innovative therapies, reporting significant progress with Mounjaro and Kisunla in cardiovascular health and Alzheimer's treatment, ...
Pharma major Eli Lilly claims its weight loss drug reduces cardiovascular risks in Type 2 diabetes patients
Eli Lilly's Mounjaro demonstrates significant cardiovascular benefits for Type 2 diabetes patients with heart disease, ...
Eli Lilly: The Best Growth Prospects Come At A Price
Eli Lilly's growth is fueled by GLP-1 blockbusters and a solid pipeline, yet high valuations and reliance on key drugs ...